Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus

A case report

Jiali Chen, MD, Yuebo Jin, MD, Chun Li, MD, Zhanguo Li, MD, PhD

Abstract

Rationale: Cyclophosphamide (CY) is an alkylating agent used widely to treat cancer and autoimmune diseases. Hyponatremia is a common adverse effect of high-dose and moderate-dose of intravenous CY, but is rare in patients treated with low-dose (<15 mg/kg).

Patient concerns: A 52-year-old woman with new-onset systemic lupus erythematosus (SLE) was treated with low-dose cyclophosphamide (8 mg/kg, CY), but showed sudden headaches, disorientation and weakness. Laboratory examinations revealed severe isovolumic hyponatremia along with low-serum osmolality and high urine osmolality.

Diagnosis: The acute hyponatremia was consistent with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and was an adverse event of low-dose CY, with no evidence of endocrine, cancer, pulmonary, or cerebral abnormalities relevant to the SIADH.

Intervention: The hyponatremia was resolved after the supplementation of NaCl solution.

Outcomes: The hyponatremia was resolved without any complications.

Lessons: Hyponatremia induced by low-dose CY should be recognized as an underlying life-threatening complication in clinical practice.

Abbreviations: AVP = arginine vasopressin, CY = cyclophosphamide, MMF = mycophenolate mofetil, SIADH = syndrome of inappropriate secretion of antidiuretic hormone, SLE = systemic lupus erythematosus.

Keywords: cyclophosphamide, hyponatremia, systemic lupus erythematosus, syndrome of inappropriate antidiuretic hormone secretion

1. Introduction

Cyclophosphamide (CY) is an alkylating agent synthesized over 50 years ago, which is used widely in the treatment of malignancy and autoimmune diseases. Its well-known adverse effects include nausea, vomiting, alopecia, bone marrow suppression, infection, hemorrhagic cystitis, sterility, and malignancy.[1] Hyponatremia is rarely seen in patients treated with low-dose (<15 mg/kg) of intravenous CY therapy,[1–3] although previous studies have been reported with the treatment of high (30–40 mg/kg)[4,5] and moderate (20–30 mg/kg) doses.[6,7] Though low-dose CY is being used widely in the treatment of rheumatic diseases, the rare adverse effect of hyponatremia is not extensively recognized in the rheumatology literature and we found only 5 cases are associated with rheumatic diseases. In this article, we report a patient with systemic lupus erythematosus (SLE) who suffered from recurrent hyponatremia following the administrations of low-dose CY. We also performed an extensive literature review of water intoxication or hyponatremia cases among patients treated with low-dose CY and analyzed the clinical characteristics of these patients.

2. Case report

A 52-year-old woman presented to our hospital in June 27, 2018, with one month history of oral ulcers, malar rash. Physical examination revealed vasculitis in her fingertips. Her leukocyte count was 2100/μL, lymphocyte proportion was 25.4%, and hemoglobin level was 98 g/L with positive Coombs test. Serum creatinine was normal and urinalysis showed hematuria and proteinuria with protein excretion of 1.32 g per day. Antinuclear
antibody, anti-double-stranded DNA, anti-Sm, and anti-Ribonucleoprotein antibody were all positive, combined with a decreased level of complement. She met the American College of Rheumatology classification criteria for SLE and received methylprednisolone at 40mg/day plus hydroxychloroquine (0.4 g/day). A week later, she was given the first administration of CY 400mg (8 mg/kg) and was well-tolerated. Six hours later, she felt unwell with headaches, and then disorientation and weakness were gradually developed. Her blood pressure was 124/68mmHg and emergency biochemistry examinations showed a significant decrease of serum sodium from 143 to 116mmol/L. The serum osmolality was 253mOsm per kilogram of water, while the urinary osmolality 506mOsm per kilogram of water, and the urinary sodium 80 mmol/L. Her computed tomography scan of brain was normal, and cerebrospinal fluid examination excluded infection. Because her hyponatremia was acute and symptomatic, she was treated with intravenous infusion of 3% NaCl solution at a rate of 30mL/h for 8hours and 0.9% NaCl at a rate of 75 ml/L for 14hours, accompanied with water restriction. Her serum sodium slowly rose to 125 mmol/L after 24hours and 131mmol/L after 48hours, and her mental status recovered. The patient made a complete recovery and was discharged on July 10, 2018, when the serum sodium reached 142mmol/L (Fig 1).

3. Discussion

Hyponatremia is the most common body fluid and electrolyte disorder in clinical practice, which is defined as an excess of water in the extracellular fluid and serum sodium <135mmol/L. The syndrome of inappropriate secretion of antidiuretic hormone secretion (SIADH) is the most prevalent cause of hyponatremia. SIADH was first reported in patients of bronchogenic carcinoma with inappropriate secretion of the arginine vasopressin (AVP). The secretion of AVP is independent of plasma osmolality and is one of the most important pathogenesis of patients with SIADH. Because not all patients with SIADH have increased serum levels of AVP, the term was inaccurate for this condition and syndrome of inappropriate antidiuresis (SIAD) was proposed as an accurate term. SIADH was first reported in patients of bronchogenic carcinoma with inappropriate secretion of the arginine vasopressin (AVP). Studies have shown that the secretion of AVP is independent of plasma osmolality and is one of the most important pathogenesis of patients with SIADH. Because not all patients with SIADH have increased serum levels of AVP, the term was inaccurate for this condition and syndrome of inappropriate antidiuresis (SIAD) was proposed as an accurate term. SIADH was first reported in patients of bronchogenic carcinoma with inappropriate secretion of the arginine vasopressin (AVP). Various etiologies can cause SIADH, and they can be categorized as related to malignant diseases, pulmonary diseases, infection, and disorders of the central nervous system. Additionally, several drugs, especially chlorpropamide, tricyclic anti-
depressants, and several cytotoxic drugs including vincristine, cyclophosphamide can stimulate the release of arginine vasopressin or enhance its action, and they could be served as causes of SIADH.[9]

Severe hyponatremia has been reported in patients treated with high-dose (30–40 mg/kg) and moderate-dose (20–30 mg/kg),[14–7] while life-threatening acute hyponatremia is rare in low-dose CY. As far, a total of 14 cases reports have been described following low-dose CY therapy (<15 mg/kg). The data is summarized in Table 1. Seven cases are associated with autoimmune diseases (AIDs), including SLE,[11–3] Sjogren syndrome,[12] pemphigus,[13] systemic sclerosis,[14] and rapidly histological glomerulonephritis.[15] The other 7 cases are about malignancy associated with multiple myeloma,[7,16] breast cancer.[17] Most of them are female except 2 men, and the average age was 56 years (range 26–69 years). These patients had active disease activity and combined therapies included corticosteroids, hydroxychloroquine, and some cytotoxic drugs including azathioprine, thalidomide, vincristine, fluorouracil, epirubicin, docetaxel, and vinorelbine. Dose of CY ranged from 500 mg to 15 mg/kg per infusion. Hyponatremia occurs 5 to 12 hours after the administration of CY with fluid intake estimated 1 to 3 L. Serum sodium was changed from 136 (range 129–138) mmol/L to 116 (106–124) mmol/L in average, accompanied with the symptoms of nausea, vomiting, seizure, weakness, and other neurological symptoms related to hyponatremia.

Reports of CY-induced hyponatremia or SIADH usually occurs 4 to 12 hours after the infusion of CY which may be related to the active alkylating metabolite of CY. The maximum antidiuretic effect of this metabolite occurs at 10 to 14 hours after drug administration though the half-life time of CY in serum is about 6 to 7 hours.[22,23] The mechanisms of water intoxication and SIADH induced by cyclophosphamide have not been clearly understood, though several hypotheses have been proposed to explain the underlying mechanisms. CY or active form of CY can either stimulate AVP release or enhance its renal effects and cause hyponatremia finally. Harlow et al[24] revealed the loss of Herring bodies and degranulation of various hypothalamic neurosecretory organelles in 1 patient who had high-dose CY with the postmortem examination. These organelles can act indirectly by causing the inappropriate secretion of AVP, which has been demonstrated with ifosfamide, a similar structural analog to CY.[25] However, Prabhu et al[26] indicated that serum ADH levels have not changed apparently after the administration of CY. Furthermore, DeFronzo et al[27] believed that alkylating metabolite of CY had a direct effect on the kidney resulting in enhanced permeability of the distal tubules to water without altering the glomerular filtration rate or urine sodium excretion. Additionally, CY might cause hyponatremia by upregulating expression of ADH receptor V2R and aquaporin 2 through suppression of interleukin-1 and tumor necrosis factor-α, which act as negative regulators of VR2 expression.[28]

Fluid intake ranging from 2 to 3 L after the administration of CY to lower the risk of hemorrhagic cystitis is an important factor for water intoxication. Bruining et al[18] reported to have extreme amounts of fluids intake in a short time may cause severe hyponatremia. The routine uses of Mesna and ingesting 1 L of fluid above patients’ usual intake in the following 24 hours may reduce the risk of water intoxication.[11]

Caution is necessary in patients with significant renal disorders because renal failure or hypoalbuminemia could prolong the half-life of CY or its alkylating metabolites and deteriorate the water-retention.[11] Besides, simultaneous administration of corticosteroid, non-steroid anti-inflammatory drugs, antidepressants, and other cytotoxic drugs may accelerate the acute water intoxication.[11]

In conclusion, the aforementioned case highlights the rare complication of water intoxication after the administration of low-dose CY. Our case, together with other reported cases, emphasizes SIADH indeed should be kept in mind in clinical practice when intravenous cyclophosphamide is applied, especially in patients with other underlying risk factors.

### Table 1
Overview of reported cases of hyponatremia or SIADH associated with low-dose cyclophosphamide.

| Ref. | Patients (age/sex) | Disease | Dose of CY used | Fluid intake (estimated, L) | Time after CY, h | Sodium before CY, mmol/L | Sodium after CY, mmol/L | Combined drug(s) |
|------|--------------------|---------|----------------|-----------------------------|-----------------|--------------------------|------------------------|------------------|
| [3]  | McCarron, 1995     | 59/Female | SLE           | 10 mg/kg                    | 2.5             | 12                       | 138                    | Pred 20 mg/d     |
| [1]  | Salido M, 2003     | 48/Female | SLE           | 12.5 mg/kg                  | 3               | 8                        | 119                    | Pred 1 mg/kg/d AZA 3 mg/kg/d |
| [2]  | Salido M, 2003     | 53/Female | SLE, SS       | 500 mg                      | 3               | 7                        | 119                    | Pred 50 mg       |
| [9]  | Koo TY, 2007       | 27/Female | Lupus nephritis | 14.8 mg/kg              | 2               | 5                        | 135                    | Pred 50 mg/HCO2 200 mg |
| [3]  | Spital, 1997       | NA       | SS            | <15 mg/kg                   | NA              | NA                       | NA                     | NA               |
| [3]  | Jayachandran NV, 2009 | 49/Female | Systemic sclerosis | 500 mg        | NA              | 24                       | NA                     | Pred 100 mg/d     |
| [13] | Kallikos Nataran, 2009 | 26/Female | Pemphigus     | <15 mg/kg                   | NA              | NA                       | NA                     | Pred 75 mg       |
| [15] | Espósito P, 2017   | 56/Male  | BGN           | 8 mg/kg                     | 2               | 48                       | 117                    | Pred 50 mg/d     |
| [14] | Webberley M.J., 1989 | 68/Male  | Multiple Myeloma | 500 mg                   | 3               | 48                       | 138                    | NA               |
| [17] | Hwang SB, 2011     | 56/Female | Breast cancer | 600 mg/m²                   | 1               | 50                       | 116                    | DOX 90 mg, DEX |
| [14] | Bruning DM, 2011   | 64/Female | Breast cancer | 500 mg/m²                   | 1.5–2.0         | 28                       | 134                    | DOX 90 mg       |
| [7]  | Gilbar FJ, 2012    | 69/Female | Multiple Myeloma | 8 mg/kg              | 1.5             | 48                       | 129                    | Pred 3 mg/d DOX 40 mg/d |
| [19] | Geng C, 2014       | 54/Female | Multiple Myeloma | 500 mg/m²                   | 2               | 13                       | 136                    | DOX 10 mg       |
| [20] | Geng C, 2014       | 58/Female | Breast cancer | 500 mg/m²                   | 2               | NA                       | NA                     | Pred 125 mg      |
| [21] | Michelle Baker, 2014 | 58/Female | Breast cancer | 15 mg/kg                     | NA              | 24                       | 117                    | DOX 12 mg, DTX 130 mg. |
| [21] | Michelle Baker, 2014 | 58/Female | Breast cancer | 15 mg/kg                     | NA              | 24                       | 117                    | DOX 12 mg, DTX 130 mg. |
| [21] | Shenren Elazzazy, 2014 | 43/Female | Breast cancer | 600 mg/m²                   | 2               | 72                       | 138                    | Chlorthalidone 12.5 mg |

AZA = azathioprine; CY = cyclophosphamide; DOX = doxorubicin; DTX = docetaxel; DVM = dexamethasone; EPI = epirubicin; FLU = fluorouracil; H2O = hydroxychloroquine; Pred = prednisolone; SIADH = syndrome of inappropriate secretion of antidiuretic hormone; SLE = systemic lupus erythematosus; SS = Sjogren syndrome; Thal = thalidomide; NA = not available; RFGN = rapidly fibrosing glomerulonephritis; VOR = vincristine.
Author contributions

Conceptualization: Jiali Chen, Chun Li.

Formal analysis: Jiali Chen.

Investigation: Jiali Chen, Chun Li.

Supervision: Yuebo Jin, Chun Li, Zhanguo Li.

Writing – original draft: Jiali Chen.

Writing – review & editing: Jiali Chen, Yuebo Jin, Chun Li, Zhanguo Li.

References

[1] Salido M, Macarron P, Hernandez-Garcia C, et al. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003;12:636–9.

[2] Koo TY, Bae SC, Park JS, et al. Water intoxication following low-dose intravenous cyclophosphamide. Electrolyte Blood Press 2007;5:50–4.

[3] McCarron M, Wright GD, Roberts SD. Water intoxication after low dose cyclophosphamide. BMJ 1995;311:292.

[4] Abe T, Takaue Y, Okamoto Y, et al. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in children undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Pediatr Hematol Oncol 1995;12:363–9.

[5] Lazarevic V, Hagg E, Wahlin A. Hiccups and severe hyponatraemia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation. Am J Hematol 2007;82:88.

[6] Lee YC, Park JS, Lee CH, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 2010;25:1320–4.

[7] Gilbar PJ, Richmond J, Wood J, et al. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide. Ann Pharmacother 2012;46:e23.

[8] Spasovski G, Vanholder R, Alloko B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014;170:G1–47.

[9] Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064–72.

[10] Schwartz WB, Bennett W, Carel P, et al. A syndrome of renal sodium loss and hyponatraemia possibly resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:329–42.

[11] Feldman BJ, Rosenthal SM, Vargas GA. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2003;352:1884–90.

[12] Spital A, Ristow S. Cyclophosphamide induced water intoxication in a woman with Sjogren’s syndrome. J Rheumatol 1997;24:2473–5.

[13] Jayachandran NV, Chandrasekharu PK, Thomas J, et al. Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis. Rheumatology (Oxford) 2009;48:89–90.

[14] Natarajan K, Srinivas CR, Jayachandran K, et al. Cyclophosphamide-induced syndrome of inappropriate antidiuretic hormone secretion. Indian J Dermatol Venereol Leprol 2009;75:629–30.

[15] Espósito P, Domenech MV, Serpieri N, et al. Severe cyclophosphamide-related hyponatraemia in a patient with acute glomerulonephritis. World J Nephrol 2017;6:217–20.

[16] Webberley MJ, Murray JA. Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin. Postgrad Med J 1989;65:950–2.

[17] Hwang SB, Lee HY, Kim HY, et al. Life-threatening acute hyponatraemia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer 2011;14:345–8.

[18] Brunning DM, van Roon EN, de Graaf H, et al. Cyclophosphamide-induced symptomatic hyponatraemia. Neth J Med 2011;69:192–5.

[19] Geng C, Tang P, Zhang Y, et al. Hyponatraemia induced by low-dose cyclophosphamide in two patients with breast cancer. Breast J 2014;20:442–3.

[20] Baker M, Markman M, Niu J. Cyclophosphamide-induced severe acute hyponatraemic encephalopathy in patients with breast cancer: report of two cases. Case Rep Oncol 2014;7:530–4.

[21] Elazzazy S, Mohamed A, Gulied A. Cyclophosphamide-induced symptomatic hyponatraemia, a rare but severe side effect: a case report. Onco Targets Ther 2014;7:1641–5.

[22] Buckner CD, Rudolph RH, Peter A. High dose cyclophosphamide therapy for malignant disease. Cancer 1972;29:357–65.

[23] Cohen JL, Jao JY, Jusko WJ. Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 1971;43:677–80.

[24] Harlow PJ, Declerck YA, Shore NA, et al. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 1979;44:896–8.

[25] Kirch C, Garchot B, German N, et al. Recurrent ifosfamide-induced hyponatraemia. Eur J Cancer 1997;33:2438–9.

[26] Pratt CB, Douglas EC, Kownar EH. A phase Y study of ifosfamide given on alternate days to treat children with brain tumors. Cancer 1993;71:3666–9.

[27] DeFronzo RA, Braine H, Colvin M, et al. Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. Ann Intern Med 1973;78:861–9.

[28] Park SJ, Kim JH, Shin JI. Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 2010;25:3453.